Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study . Ann Intern Med 1988;;109:280-7.
Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome . Ann Intern Med 1984;;100:495-9.
Polk BF, Fox R, Brookmeyer R, et al. Predictors of acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men . N Engl J Med 1987;;316:61-6.
Masur H, Ognibene FP, Yarchoan RY, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus infected individuals . Ann Intern Med (in press).
Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled study . N Engl J Med 1987;;317:185-91.
National Institute of Allergy and Infectious Diseases, USA. The safety and efficacy of two doses of zidovudine in the treatment of patients with AIDS . (Abstract) IV International Conference on AIDS . Book 2. Stockholm,
Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis . N Engl J Med 1977;;297:1419-26.
Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonia . N Engl J Med 1987;;316:1627-32.
Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS . JAMA 1988;;259:1185-9.
Leoung GS, Montgomery AB, Abrams DA, et al. Aerosol pentamidine for Pneumocystis carinii pneumonia (PCP): A randomized trial of 439 patients . (Abstract) IV International Conference on AIDS . Book 1. Stockholm,
Bach M-A, Phan-Dinh-Tuy F, Bach J-F, et al. Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodies . J Immunol 1981;;127:980-2.
CDC. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET) . MMWR 1989;;38:236-8,243-50.
Abd AG, Nierman DM, Ilowite JS, Pierson RN, Lomis Bell AL. Bilateral upper lobe Pneumocystis carinii pneumonia in a patient receiving inhaled pentamidine prophylaxis . Chest 1988;;94:329-31.
Poblete RB, Rodriguez K, Foust RT, Reddy KR, Saldana MJ. Pneumocystis carinii hepatitis in the acquired immunodeficiency syndrome (AIDS) . Ann Intern Med 1989;;9:737-8.
CDC. Human immunodeficiency virus infection in the United States: a review of current knowledge . MMWR 1987;;36(
Kidd PG, Vogt RF Jr. Report of the workshop on the evaluation of T-cell subsets during HIV infection and AIDS . Clin Immunol Immunopathol 1989; (in press).
Taylor JMG, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use . J AIDS 1989;;2:114-24.
CDC. Mycobacterium tuberculosis transmission in a health clinic—Florida, 1988 . MMWR 1989;;38:256-64.
LyphoMed, Inc. A treatment IND for the use of aerosolized pentamidine in HIV-infected individuals at high risk for Pneumocystis carinii pneumonia . Rosemont, Illinois: LyphoMed, Inc., 1989;.
Henry Masur, M.D., National Institutes of Health (Chairman); Carmen Allegra, M.D., National Cancer Institute; Donald Armstrong, M.D., Memorial Sloan-Kettering Cancer Center; Victor DeGruttola, D.Sc., Harvard University Statistical Center; Susan S. Ellenberg, Ph.D., National Institute of Allergy and Infectious Diseases; David Feigal, M.D., San Francisco General Hospital; Judith Feinberg, M.D., National Institute of Allergy and Infectious Diseases; Margaret A. Fischl, M.D., University of Miami School of Medicine; Walter T. Hughes, M.D., St. Jude Children's Research Hospital; Harold Jaffe, M.D., Centers for Disease Control; John Mills, M.D., San Francisco General Hospital; A. Bruce Montgomery, M.D., SUNY at Stony Brook; Alvaro Muñoz, Ph.D., Johns Hopkins School of Public Health; John P. Phair, M.D., Northwestern University Medical School; Frank Richards, M.D., Yale University; Fred Sattler, M.D., University of Southern California; Gerald Smaldone, M.D., Ph.D., SUNY at Stony Brook; Carol Braun Trapnell, M.D., Food and Drug Administration; Sten H. Vermund, M.D., M.Sc., National Institute of Allergy and Infectious Diseases. Consultants to the Task Force were Judith Falloon, M.D., National Institutes of Health; Michael Polis, M.D., M.P.H., National Institutes of Health; Michael Sampson, M.D., SUNY at Stony Brook.